Genmab expands collaboration with Seattle Genetics

Published: 19-Apr-2011

Forms second antibody-drug conjugate (ADC) research agreement

Danish biotechnology firm Genmab has entered into a second antibody-drug conjugate (ADC) research collaboration with Seattle Genetics in the US.

Under the new agreement, Genmab has acquired the rights to use Seattle Genetics’ ADC technology with HuMax-CD74, an antibody in pre-clinical development to target CD74, which is expressed on a range of haematological malignancies and solid tumours.

Seattle Genetics will receive an upfront payment and also has co-development and co-commercialisation options for any resulting ADC products at the end of Phase I clinical development.

Genmab is responsible for research, manufacturing, pre-clinical development and Phase I clinical evaluation of ADCs under this new collaboration.

‘The expanded collaboration with Genmab provides us with another opportunity to augment our future ADC product pipeline based on data from a phase I clinical trial,’ said Eric Dobmeier, chief business officer of Seattle Genetics.

‘We now have co-development options for four of our collaborators’ ADC programmes, reflecting our ability to maximise the potential of our technology through strategic collaborations with organisations that have complementary capabilities.’

You may also like